The evidence supports over-the-counter access to progestin-only pills: A research summary

HRA Pharma has submitted an application to the FDA for an over-the-counter (OTC) progestin-only birth control pill (POP). If approved, Opill would be the first OTC birth control pill available in the United States. This research summary highlights the safety and efficacy of POPs, experiences with and interest in using them, and the challenges and barriers to accessing birth control pills in the current prescription-only environment.

Last updated: April 1, 2024

Previous
Previous

Letter from Free the Pill coalition to FDA Commissioner Dr. Robert M. Califf

Next
Next

The Food and Drug Administration should approve over-the-counter oral contraception without an age restriction